Leading molecular markers, such as IDH1 and IDH2 mutations and codeletions in 1p and 19q chromosomes [26], divide gliomas into three molecular different subtypes: IDH-mutant (1p19q codeleted), IDH-mutant (1p19q intact) and IDH-wild-type gliomas [27]. This evidence concerns the gene IDH2 and central nervous system cancer.